SAREUM HOLDINGS PLC – Exercise Of Warrants
RNS Number : 3756R Sareum Holdings PLC 19 August 2026 Sareum Holdings plc (“Sareum” or the “Company“) Exercise of
RNS Number : 3756R Sareum Holdings PLC 19 August 2026 Sareum Holdings plc (“Sareum” or the “Company“) Exercise of
RNS Number : 8165P Sareum Holdings PLC 07 August 2026 Sareum Holdings plc (“Sareum” or the “Company“) Exercise of
RNS Number : 8860M Sareum Holdings PLC 20 July 2026 Sareum Holdings PLC (“Sareum” or the “Company”) Completion of
Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces its results for the year ended 30 June 2020.
Sareum Holdings plc (AIM: SAR), the specialised small molecule drug development business, announces its results for the year ended 30 June 2019 and provides an update of significant post-period events. The Company will host a conference call today at 10.00 a.m. (see details below).
Sareum Holdings plc (AIM: SAR), the specialised small molecule drug development business, provides the following trading update ahead of its full year results for the year ended 30 June 2019. Sareum expects to report its full audited annual results by mid-October 2019.
Sareum Holdings PLC, the specialist small molecule drug development business announced on 25 June 2019 the launch of a fundraising comprising a placing by Hybridan LLP in conjunction with an offer via PrimaryBid.
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces its half-yearly results for the six months ended 31 December 2018 and provides an update of significant post-period events.
Sareum Holdings plc (AIM: SAR), the specialist in small molecule drug development, announces its results for the year ended 30 June 2018 and provides an update of significant post-period events.
Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announced that it has regained worldwide rights to preclinical-stage small molecule inhibitors of Aurora and FLT3 kinases that have shown potential in acute myeloid leukaemia (AML) and other haematological cancers. The rights have been returned by Hebei Medical University Biomedical Engineering Center (HMUBEC), a pharmaceutical research and development group based in China that has been conducting preclinical development activities.